Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Pulmonary complications of inflammatory bowel disease

Steven E Weinberger, MD
Mark A Peppercorn, MD
Section Editors
Kevin R Flaherty, MD, MS
Paul Rutgeerts, MD, PhD, FRCP
Deputy Editor
Helen Hollingsworth, MD


Inflammatory bowel disease (IBD) is associated with a variety of conditions outside of the gastrointestinal tract, termed extraintestinal manifestations of IBD (table 1). Since the original report in 1976 of six patients with unexplained chronic purulent sputum production, involvement of the respiratory tract, although relatively rare, has been increasingly recognized in patients with IBD [1].

The pulmonary complications of IBD including those related to the medications used to treat IBD are discussed here. An approach to the evaluation and diagnosis of interstitial pneumonia and discussions of the clinical manifestations of Crohn's disease and ulcerative colitis are provided separately. (See "Approach to the adult with interstitial lung disease: Clinical evaluation" and "Approach to the adult with interstitial lung disease: Diagnostic testing" and "Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults" and "Clinical manifestations, diagnosis and prognosis of Crohn disease in adults".)


Case series vary in terms of the proportions of patients with ulcerative colitis and Crohn’s disease who have associated lung disease [2-4]. In a series of 52 patients with IBD, abnormal pulmonary function tests were more common in patients with Crohn’s disease than ulcerative colitis (25 versus 6 percent), but abnormal computed tomography was seen in approximately 50 percent of patients with ulcerative colitis or Crohn’s [3]. In a separate series of 33 patients with IBD-associated lung involvement, 27 had ulcerative colitis and six had Crohn's disease [2].


The pathogenesis of pulmonary parenchymal disease and serositis associated with IBD is unknown. However, the more common airway inflammatory changes are thought to represent the same type of inflammatory changes that occur in the bowel [5]. (See "Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease".)


Pulmonary complications of IBD include inflammation of small and large airways, pulmonary parenchymal disease, serositis, and pulmonary embolism [6,7]. These abnormalities are generally related to the underlying bowel disease, although interstitial lung disease can also be induced by administration of certain drugs, such as sulfasalazine, 5-aminosalicylic acid, methotrexate, azathioprine, and infliximab [8-12]. Patients with IBD may present with cough, dyspnea, chest pain, or an abnormal chest radiograph obtained for another reason. Often the initial history (including current medications) and physical examination will focus attention on a given type of lung involvement (eg, airway versus parenchymal).

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Jul 08, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Kraft SC, Earle RH, Roesler M, Esterly JR. Unexplained bronchopulmonary disease with inflammatory bowel disease. Arch Intern Med 1976; 136:454.
  2. Camus P, Piard F, Ashcroft T, et al. The lung in inflammatory bowel disease. Medicine (Baltimore) 1993; 72:151.
  3. Tunc B, Filik L, Bilgic F, et al. Pulmonary function tests, high-resolution computed tomography findings and inflammatory bowel disease. Acta Gastroenterol Belg 2006; 69:255.
  4. Herrlinger KR, Noftz MK, Dalhoff K, et al. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am J Gastroenterol 2002; 97:377.
  5. Higenbottam T, Cochrane GM, Clark TJ, et al. Bronchial disease in ulcerative colitis. Thorax 1980; 35:581.
  6. Mahadeva R, Walsh G, Flower CD, Shneerson JM. Clinical and radiological characteristics of lung disease in inflammatory bowel disease. Eur Respir J 2000; 15:41.
  7. Sostegni R, Daperno M, Pera A. Pulmonary manifestations of inflammatory bowel disease. Dig Liver Dis 2007; 39:239.
  8. Casey MB, Tazelaar HD, Myers JL, et al. Noninfectious lung pathology in patients with Crohn's disease. Am J Surg Pathol 2003; 27:213.
  9. Parry SD, Barbatzas C, Peel ET, Barton JR. Sulphasalazine and lung toxicity. Eur Respir J 2002; 19:756.
  10. Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2003; 9:104.
  11. Kuzela L, Vavrecka A, Prikazska M, et al. Pulmonary complications in patients with inflammatory bowel disease. Hepatogastroenterology 1999; 46:1714.
  12. Black H, Mendoza M, Murin S. Thoracic manifestations of inflammatory bowel disease. Chest 2007; 131:524.
  13. Kuźniar T, Sleiman C, Brugière O, et al. Severe tracheobronchial stenosis in a patient with Crohn's disease. Eur Respir J 2000; 15:209.
  14. Mansi A, Cucchiara S, Greco L, et al. Bronchial hyperresponsiveness in children and adolescents with Crohn's disease. Am J Respir Crit Care Med 2000; 161:1051.
  15. Bayraktaroglu S, Basoglu O, Ceylan N, et al. A rare extraintestinal manifestation of ulcerative colitis: tracheobronchitis associated with ulcerative colitis. J Crohns Colitis 2010; 4:679.
  16. Camus P, Colby TV. Bronchiectasis in inflammatory bowel disease. Eur Respir Monogr 2011; 52:163.
  17. Garg K, Lynch DA, Newell JD. Inflammatory airways disease in ulcerative colitis: CT and high-resolution CT features. J Thorac Imaging 1993; 8:159.
  18. Spira A, Grossman R, Balter M. Large airway disease associated with inflammatory bowel disease. Chest 1998; 113:1723.
  19. Vandenplas O, Casel S, Delos M, et al. Granulomatous bronchiolitis associated with Crohn's disease. Am J Respir Crit Care Med 1998; 158:1676.
  20. Kirkcaldy J, Lim WS, Jones A, Pointon K. Stridor in Crohn disease and the use of infliximab. Chest 2006; 130:579.
  21. Plataki M, Tzortzaki E, Lambiri I, et al. Severe airway stenosis associated with Crohn's disease: case report. BMC Pulm Med 2006; 6:7.
  22. Janssen WJ, Bierig LN, Beuther DA, Miller YE. Stridor in a 47-year-old man with inflammatory bowel disease. Chest 2006; 129:1100.
  23. Casella G, Villanacci V, Di Bella C, et al. Pulmonary diseases associated with inflammatory bowel diseases. J Crohns Colitis 2010; 4:384.
  24. Tzanakis N, Bouros D, Samiou M, et al. Lung function in patients with inflammatory bowel disease. Respir Med 1998; 92:516.
  25. Marvisi M, Borrello PD, Brianti M, et al. Changes in the carbon monoxide diffusing capacity of the lung in ulcerative colitis. Eur Respir J 2000; 16:965.
  26. Smiéjan JM, Cosnes J, Chollet-Martin S, et al. Sarcoid-like lymphocytosis of the lower respiratory tract in patients with active Crohn's disease. Ann Intern Med 1986; 104:17.
  27. Bewig B, Manske I, Böttcher H, et al. Crohn's disease mimicking sarcoidosis in bronchoalveolar lavage. Respiration 1999; 66:467.
  28. Theodoropoulos G, Archimandritis A, Davaris P, et al. Ulcerative colitis and sarcoidosis: a curious association-report of a case. Dis Colon Rectum 1981; 24:308.
  29. Tanigawa K, Sugiyama K, Matsuyama H, et al. Mesalazine-induced eosinophilic pneumonia. Respiration 1999; 66:69.
  30. Saltzman K, Rossoff LJ, Gouda H, Tongia S. Mesalamine-induced unilateral eosinophilic pneumonia. AJR Am J Roentgenol 2001; 177:257.
  31. Camus P. Interstitial lung disease from drugs, biologics, and radiation. In: Interstitial Lung Disease, 5th, Schwatrz MI, King TE, Jr (Eds), People's Publishing House, Shelton, CT 2011. p.637.
  32. Nelson BA, Kaplan JL, El Saleeby CM, et al. Case records of the Massachusetts General Hospital. Case 39-2014. A 9-year-old girl with Crohn’s disease and pulmonary nodules. N Engl J Med 2014; 371:2418.
  33. Kasuga I, Yanagisawa N, Takeo C, et al. Multiple pulmonary nodules in association with pyoderma gangrenosum. Respir Med 1997; 91:493.
  34. Freeman HJ, Davis JE, Prest ME, Lawson EJ. Granulomatous bronchiolitis with necrobiotic pulmonary nodules in Crohn's disease. Can J Gastroenterol 2004; 18:687.
  35. Rosenbaum AJ, Murphy PJ, Engel JJ. Pleurisy during the course of ulcerative colitis. J Clin Gastroenterol 1983; 5:517.
  36. Hooper C, Lee YC, Maskell N, BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 Suppl 2:ii4.
  37. Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009; 84:979.
  38. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99:97.
  39. Bonderman D, Jakowitsch J, Adlbrecht C, et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 2005; 93:512.
  40. Quera R, Shanahan F. Thromboembolism--an important manifestation of inflammatory bowel disease. Am J Gastroenterol 2004; 99:1971.
  41. Sonoda K, Ikeda S, Mizuta Y, et al. Evaluation of venous thromboembolism and coagulation-fibrinolysis markers in Japanese patients with inflammatory bowel disease. J Gastroenterol 2004; 39:948.
  42. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53:542.
  43. Bonderman D, Skoro-Sajer N, Jakowitsch J, et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation 2007; 115:2153.
  44. Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol 2011; 106:713.
  45. Novacek G, Weltermann A, Sobala A, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139:779.
  46. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375:657.
  47. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103:2272.
  48. Kappelman MD, Horvath-Puho E, Sandler RS, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011; 60:937.
  49. Nguyen GC, Bernstein CN, Bitton A, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 2014; 146:835.
  50. Yuhara H, Steinmaus C, Corley D, et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37:953.
  51. Bitton A, Peppercorn MA, Hanrahan JP, Upton MP. Mesalamine-induced lung toxicity. Am J Gastroenterol 1996; 91:1039.
  52. Foucher P, Camus P. Pneumotox online: the drug-induced lung diseases. www.pneumotox.com (Accessed on April 07, 2009).
  53. Hamadeh MA, Atkinson J, Smith LJ. Sulfasalazine-induced pulmonary disease. Chest 1992; 101:1033.
  54. Salerno SM, Ormseth EJ, Roth BJ, et al. Sulfasalazine pulmonary toxicity in ulcerative colitis mimicking clinical features of Wegener's granulomatosis. Chest 1996; 110:556.
  55. Jain N, Petruff C, Bandyopadhyay T. Mesalamine lung toxicity. Conn Med 2010; 74:265.
  56. Margagnoni G, Papi V, Aratari A, et al. Methotrexate-induced pneumonitis in a patient with Crohn's disease. J Crohns Colitis 2010; 4:211.
  57. Brechmann T, Heyer C, Schmiegel W. [Methotrexate-induced pneumonitis in a woman with Crohn's disease]. Dtsch Med Wochenschr 2007; 132:1759.
  58. Ananthakrishnan AN, Attila T, Otterson MF, et al. Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J Clin Gastroenterol 2007; 41:682.
  59. Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004; 127:730.
  60. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098.
  61. Weatherhead M, Masson S, Bourke SJ, et al. Interstitial pneumonitis after infliximab therapy for Crohn's disease. Inflamm Bowel Dis 2006; 12:427.
  62. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011; 41:256.
  63. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86:242.
  64. Heraganahally SS, Au V, Kondru S, et al. Pulmonary toxicity associated with infliximab therapy for ulcerative colitis. Intern Med J 2009; 39:629.
  65. Veerappan SG, O'Morain CA. Infliximab-associated alveolitis after treatment for severe left-sided ulcerative colitis. Eur J Gastroenterol Hepatol 2009; 21:830.